Nielsen Rikke V, Fuster Valentin, Bundgaard Henning, Fuster Jose J, Johri Amer M, Kofoed Klaus F, Douglas Pamela S, Diederichsen Axel, Shapiro Michael D, Nicholls Stephen J, Nordestgaard Børge G, Lindholt Jes S, MacRae Calum, Yuan Chun, Newby David E, Urbina Elaine M, Bergström Göran, Ridderstråle Martin, Budoff Matthew J, Bøttcher Morten, Raitakari Olli T, Hansen Thomas H, Näslund Ulf, Sillesen Henrik, Eldrup Nikolaj, Ibanez Borja
Department of Medical Science, Novo Nordisk Foundation, Hellerup, Denmark; Department of Cardiothoracic Anesthesiology, Rigshospitalet University Hospital Copenhagen, Copenhagen, Denmark.
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Mount Sinai Fuster Heart Hospital, New York, New York, USA.
J Am Coll Cardiol. 2024 May 28;83(21):2112-2127. doi: 10.1016/j.jacc.2024.02.053.
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of patients with CVD. When considering that atherosclerosis develops over decades, there is potentially great opportunity for prevention of associated events such as myocardial infarction and stroke. Subclinical atherosclerosis has been identified in its early stages in young individuals; however, there is no consensus on how to prevent progression to symptomatic disease. Given the growing burden of CVD, a paradigm shift is required-moving from late management of atherosclerotic CVD to earlier detection during the subclinical phase with the goal of potential cure or prevention of events. Studies must focus on how precision medicine using imaging and circulating biomarkers may identify atherosclerosis earlier and determine whether such a paradigm shift would lead to overall cost savings for global health.
心血管疾病(CVD)仍然是全球发病和死亡的主要原因,对全球医疗保健系统的能力构成挑战。动脉粥样硬化是三分之二心血管疾病患者潜在的病理生理实体。考虑到动脉粥样硬化的发展需要数十年时间,预防诸如心肌梗死和中风等相关事件存在着巨大的潜在机会。亚临床动脉粥样硬化在年轻人中已被发现处于早期阶段;然而,对于如何预防其进展为有症状疾病尚无共识。鉴于心血管疾病负担日益加重,需要进行范式转变——从动脉粥样硬化性心血管疾病的晚期管理转向亚临床阶段的早期检测,目标是潜在地治愈或预防相关事件。研究必须聚焦于利用成像和循环生物标志物的精准医学如何能更早地识别动脉粥样硬化,并确定这种范式转变是否会为全球健康带来总体成本节约。